- Home
- VINP vs AUTL Comparison
VINP vs AUTL Comparison
Compare VINP & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- AUTL
- Stock Information
- Founded
- VINP 2009
- AUTL 2014
- Country
- VINP Brazil
- AUTL United Kingdom
- Employees
- VINP N/A
- AUTL N/A
- Industry
- VINP Investment Managers
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VINP Finance
- AUTL Health Care
- Exchange
- VINP Nasdaq
- AUTL Nasdaq
- Market Cap
- VINP 636.2M
- AUTL 625.4M
- IPO Year
- VINP 2021
- AUTL 2018
- Fundamental
- Price
- VINP $10.20
- AUTL $1.27
- Analyst Decision
- VINP Strong Buy
- AUTL Strong Buy
- Analyst Count
- VINP 2
- AUTL 5
- Target Price
- VINP $13.50
- AUTL $9.12
- AVG Volume (30 Days)
- VINP 36.3K
- AUTL 4.4M
- Earning Date
- VINP 11-06-2025
- AUTL 11-11-2025
- Dividend Yield
- VINP 6.41%
- AUTL N/A
- EPS Growth
- VINP N/A
- AUTL N/A
- EPS
- VINP 0.50
- AUTL N/A
- Revenue
- VINP $153,475,995.00
- AUTL $29,934,000.00
- Revenue This Year
- VINP $68.12
- AUTL $641.63
- Revenue Next Year
- VINP $14.85
- AUTL $109.21
- P/E Ratio
- VINP $20.18
- AUTL N/A
- Revenue Growth
- VINP 76.11
- AUTL 185.17
- 52 Week Low
- VINP $8.66
- AUTL $1.11
- 52 Week High
- VINP $10.99
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- VINP 58.84
- AUTL 24.20
- Support Level
- VINP $9.75
- AUTL $1.30
- Resistance Level
- VINP $10.09
- AUTL $1.46
- Average True Range (ATR)
- VINP 0.22
- AUTL 0.09
- MACD
- VINP 0.00
- AUTL 0.01
- Stochastic Oscillator
- VINP 84.91
- AUTL 2.63
About VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.